Skip Navigation

European Heart Journal 2000 21(15):1216-1231; doi:10.1053/euhj.2000.2249
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (160)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haverkamp, W
Right arrow Articles by Shah, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haverkamp, W
Right arrow Articles by Shah, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Policy Conference

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology

W Haverkamp, G Breithardtf1, A.J Camm, M.J Janse, M.R Rosen, C Antzelevitch, D Escande, M Franz, M Malik, A Moss and R Shah

f1 Correspondence: Prof Dr med Günter Breithardt, Dr med Wilhelm Haverkamp, Medizinische Klinik und Poliklinik, Innere Medizin C, D-48129 Münster, Germany

References

  1. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation. 1964;30:17–26[Free Full Text]
  2. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088–1093[CrossRef][Web of Science][Medline]
  3. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806–817[Abstract]
  4. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsades de pointes due to quinidine: observations in 31 patients. Am Heart J. 1984;107:425–430[CrossRef][Web of Science][Medline]
  5. Haverkamp W, Martinez RA, Hief C. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol. 1997;30:487–495[Abstract]
  6. Lehmann MH, Hardy S, Archibald D, Quart B, McNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2535–2541[Abstract/Free Full Text]
  7. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol. 1997;80:82G–89G[CrossRef][Medline]
  8. Torp-Pederson C, Moller M, Bloch-Thomsen PE. for The Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:879–911[Free Full Text]
  9. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Van der Lugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613–1621[Abstract/Free Full Text]
  10. Zipes DP. Unwitting exposure to risk. Cardiol Rev. 1993;:1–3
  11. Rosen MR. Of oocytes and runny noses. Circulation. 1996;94:607–609[Free Full Text]
  12. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol. 1998;9:1114–1116[Web of Science][Medline]
  13. Veldkamp MW. Is the slowly activating component of the delayed rectifier current, IKs, absent from undiseased human ventricular myocardium? Cardiovasc Res. 1998;40:433–435[Free Full Text]
  14. Varro A, Balati B, Iost N. The role of the delayed rectifier component Iks in dog ventricular muscle and Purkinje fiber repolarization. J Physiol. 2000;523:67–81[Abstract/Free Full Text]
  15. Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of M cells. Circ Res. 1995;76:351–365[Abstract/Free Full Text]
  16. Salata JJ, Jurkiewicz N, Jow B. IKof rabbit ventricle is composed of two currents: evidence for IKs. Am J Physiol. 1996;271:H2477–2489
  17. Ye L, Feng J, Li GR, Nattel S. Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol. 1996;272:H1292–H1301[Web of Science]
  18. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42:270–283[Free Full Text]
  19. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol. 1994;23:259–277[Abstract]
  20. Viswanathan PC, Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc Res. 1999;42:530–542[Abstract/Free Full Text]
  21. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Lindhardt G. Proarrhythmic effects of class III agent almokalant: importance of infusion rate, QT dispersion and early after depolarizations. Cardiovasc Res. 1993;27:2186–2193[Abstract/Free Full Text]
  22. Burashnikov A, Antzelevitch C. Acceleration-induced action potential prolongation and early afterdepolarizations. J Cardiovasc Electrophysiol. 1998;9:934–948[Web of Science][Medline]
  23. El-Sherif N, Caref FB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res. 1996;79:474–492[Abstract/Free Full Text]
  24. Surawicz B. Electrophysiological substrate for Torsade de pointes: Dispersion of refractoriness or early afterdepolarizations. J Am Coll Cardiol. 1989;14:172–184[Abstract]
  25. Verduyn SC, Vos MA, Van der Zande J, Van der Hulst FF, Wellens HJJ. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Cardiovasc Res. 1997;34:453–463[Abstract/Free Full Text]
  26. Antzelevitch C, Shimizu W, Yan GX. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999;10:1124–1152[Web of Science][Medline]
  27. Yan G-X, Shimizu W, Antzelevitch C. Characteristics and distribution of M-cells in arterially perfused canine left ventricular wedge preparations. Circulation. 1998;98:1921–1927[Abstract/Free Full Text]
  28. Janse MJ, Capucci A, Coronel R, Fabius MAW. Variability of recovery of excitability in the normal canine and the ischaemic porcine heart. Eur Heart J. 1985;6:41–50
  29. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiological properties of epicardium, midmyocardium, and endocardium. In vitro and in vivo correlations. Circulation. 1996;94:1981–1988[Abstract/Free Full Text]
  30. Merot J, Charpentier F, Poirier JM, Coutris J, Weissenburger J. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: Interactions with acute sotalol. Cardiovasc Res. 1999;44:303–314[Abstract/Free Full Text]
  31. Mohammed S, Zhou Z, Gong Q, January CT. Blockade of the HERG human cardiac K+channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 1997;273:H2534–2538
  32. Vitola J, Vukanovic J, Roden DM. Cisapride-induced Torsade de Pointes. J Cardiovasc Electrophysiol. 1998;9:1109–1113[Web of Science][Medline]
  33. Roden DM, Spooner PM. Inherited long QT syndromes. A paradigm for understanding arrhythmias. J Cardiovasc Electrophysiol. 1999;10:1664–1683[Web of Science][Medline]
  34. Houltz B, Darpö B, Edvardsson N, Blomstrom P, Brachmann J, Crijns HJ, Jensen SM, Svernhage E, Vallin H, Swedberg K. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. PACE. 1998;21:1044–1057
  35. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97:175–187[CrossRef][Web of Science][Medline]
  36. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: Clinical impact. Circulation. 1999;99:529–533[Abstract/Free Full Text]
  37. Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: Predicting torsades de pointes. PACE. 1998;21:1029–1034
  38. Soffer J, Dreifus LS, Michelson EL. Polymorphous ventricular tachycardia associated with normal and long Q-T intervals. Am J Cardiol. 1982;49:2021–2029[CrossRef][Web of Science][Medline]
  39. Breithardt G, Seipel L, Haerten K. Paradoxic response to disopyramide and quinidine. Z Kardiol. 1980;69:556–561[Web of Science][Medline]
  40. Wald RW, Waxman MB, Colman JM. Torsade de pointes ventricular tachycardia. A complication of disopyramide shared with quinidine. J Electrocardiol. 1981;14:301–307[Web of Science][Medline]
  41. Hohnloser SH, van der Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26:852–858[Abstract]
  42. Dascal N. The use of Xenopus oocytes for the study of ion channels. Crit Rev Biochem. 1987;22:341–356
  43. Stühmer W, Parekh AB. Electrophysiological recordings from Xenopus oocytes. Sackmann B, Neher E. Single-Channel Recordings. New York: Plenum Press; 1995. p. 341–356
  44. Fishman GI, McDonald TV. Gene transfer of membrane channel proteins. Zipes DP, Jalife J. Cardiac Electrophysiology. From Cell to Bedside. Philadelphia: Saunders Company; 2000. p. 58–66
  45. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992;262:99–108[Abstract/Free Full Text]
  46. January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res. 1989;64:977–990[Abstract/Free Full Text]
  47. Busch AE, Malloy K, Groh WJ, Varnum MD, Adelman JP, Maylie J. The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes. Biochem Biophys Res Commun. 1994;202:265–270[CrossRef][Web of Science][Medline]
  48. Coronel R, Opthof T, Taggart P, Tygat J, Veldkamp M. Differential electrophysiology of repolarization from clone to clinic. Cardiovasc Res. 1997;33:503–517[Free Full Text]
  49. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 1996;94:1471–1474[Abstract/Free Full Text]
  50. Pinney SP, Koller BS, Franz MR, Woosley RL. Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol. 1995;25:30–34[Web of Science][Medline]
  51. Eckardt L, Haverkamp W, Mertens H. Drug related torsade de pointes in the isolated rabbit heart: Comparison of clofilium, d,l-sotalol and erythromycin. J Cardiovasc Pharmacol. 1998;32:425–434[CrossRef][Web of Science][Medline]
  52. Zabel M, Hohnloser SH, Behrens S, Li Y-G, Woosley RL, Franz MR. Electrophysiologic features of torsade de pointes: Insights from a new rabbit heart model. J Cardiovasc Electrophysiol. 1997;8:1148–1158[Web of Science][Medline]
  53. Johna R, Mertens H, Haverkamp W. Clofilium in the isolated perfused rabbit heart: A new model to study proarrhythmia by class III antiarrhythmic drugs. Basic Res Cardiol. 1998;93:127–135[CrossRef][Web of Science][Medline]
  54. Sosunov EA, Gainullin RZ, Danilo PJ, Anyukhovsky EP, Kirchengast M, Rosen MR. Electrophysiological effects of LU111995 on canine hearts: In vivo and in vitro studies. J Pharmacol Exp Ther. 1999;290:146–152[Abstract/Free Full Text]
  55. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential? J Pharmacol Exp Ther. 1997;282:220–227[Abstract/Free Full Text]
  56. Detweiler DK. Electrocardiography in toxicological studies. Sipes IG, McQueen CA, Gandolfi AJ. Comprehensive Toxicology. New York: Pergamon Press; 1977. p. 95–114
  57. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol. 1990;16:276–285[Web of Science][Medline]
  58. Chezalviel-Guilbert F, Davy JM, Poirier JM, Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol. 1995;26:787–792[Abstract]
  59. Weissenburger J, Davy JM, Chezalviel F. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther. 1991;259:871–883[Abstract/Free Full Text]
  60. Vos MA, Verduyn SC, Gorgels AP, Lipcsei GC, Wellens HJJ. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation. 1995;91:864–872[Abstract/Free Full Text]
  61. Vos MA, de Groot SHM, Verduyn SC. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation. 1998;98:1125–1135[Abstract/Free Full Text]
  62. Committee for Proprietary Medicinal Products (CPMP), Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, 1997
  63. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol. 1993;72:22B–23B
  64. Ahnve S. Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J. 1985;109:568–574[CrossRef][Web of Science][Medline]
  65. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:797–801[CrossRef][Web of Science][Medline]
  66. Hnatkova K, Malik M. ‘Optimum’ formulae for heart rate correction of the QT interval. PACE. 1999;22:1683–1687
  67. Honig, PK, Wortham, DC, Zamani, K, Conner, DP, Mullin, JC, Cantilena, LR, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 1993, 269, 1513, 18
  68. Bauman JL, Sanoski CA, Chan LN. Pharmacokinetic and pharmacodynamic drug interactions with antiarrhythmic agents. Cardiol Rev. 1997;5:292–304
  69. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, Moye L. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J. 1996;131:472–480[CrossRef][Web of Science][Medline]
  70. Cavuto NJ, Woosley RL, Sale M, Bates DW, Leape LL. Pharmacies and prevention of potentially fatal drug interactions. JAMA. 1996;275:1086–1087[Abstract/Free Full Text]
  71. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA,. 1996;275:1339–1341[Abstract/Free Full Text]
  72. Anonymous, ‘Janssen Propulsid Prescribing For Inpatients Questioned in Three Studies’. F-D-C Report ‘The Pink Sheet’ 1998, 60, 26
  73. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Circulation. 1996;93:407–411[Abstract/Free Full Text]
  74. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686–690[Abstract/Free Full Text]
  75. Makkar RR, Fromm BS, Steinman RT, Leissner MD, Lehmann MH. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA. 1993;270:2547–2590
  76. Liu X-K, Katchman A, Drici M-D. Gender differences in the cycle-length dependent QT and potassium currents in rabbits. J Pharm Exp Ther. 1998;285:672–679[Abstract/Free Full Text]
  77. Vermeulen JT, McGuire MA, Opthof T. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res. 1994;28:1547–1554[Web of Science][Medline]
  78. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 1996;94:817–823[Abstract/Free Full Text]
  79. Hirao H, Shimizu W, Kurita T. Frequency-dependent electrophysiological properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol. 1996;28:1269–1277[Abstract]
  80. Sun Z-H, Swan H, Viitasalo M, Toivonen L. Effects of epinephrine and phenylephrine of QT interval dispersion in congenital long QT syndrome. J Am Coll Cardiol. 1998;31:1400–1405[Abstract/Free Full Text]
  81. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome. Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 1998;98:2314–2322[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
S. Eker, A. Sarandol, C. Akkaya, E. Sivrioglu, and S. Kirli
The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases
J Psychopharmacol, November 1, 2009; 23(8): 993 - 996.
[Abstract] [PDF]

Home page
 J Clin PharmacolHome page
C. Graff, J. Matz, E. B. Christensen, M. P. Andersen, J. K. Kanters, E. Toft, S. Pehrson, T. B. Hardahl, J. Nielsen, and J. J. Struijk
Quantitative Analysis of T-wave Morphology Increases Confidence in Drug-Induced Cardiac Repolarization Abnormalities: Evidence From the Investigational IKr Inhibitor Lu 35-138
J. Clin. Pharmacol., November 1, 2009; 49(11): 1331 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 Circ Arrhythm ElectrophysiolHome page
H. Itoh, T. Sakaguchi, W.-G. Ding, E. Watanabe, I. Watanabe, Y. Nishio, T. Makiyama, S. Ohno, M. Akao, Y. Higashi, et al.
Latent Genetic Backgrounds and Molecular Pathogenesis in Drug-Induced Long-QT Syndrome
Circ Arrhythm Electrophysiol, October 1, 2009; 2(5): 511 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Circ Arrhythm ElectrophysiolHome page
A. Burashnikov, W. Shimizu, and C. Antzelevitch
Fever Accentuates Transmural Dispersion of Repolarization and Facilitates Development of Early Afterdepolarizations and Torsade de Pointes Under Long-QT Conditions
Circ Arrhythm Electrophysiol, August 1, 2008; 1(3): 202 - 208.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
J. Koistinen, M. Valtonen, J. Savola, and J. Airaksinen
Thoracoscopic microwave ablation of atrial fibrillation
Interactive CardioVascular and Thoracic Surgery, December 1, 2007; 6(6): 695 - 698.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
O. T. Mytton, E. A. Ashley, L. Peto, R. N. Price, Y. La, R. Hae, P. Singhasivanon, N. J. White, and F. Nosten
Electrocardiographic Safety Evaluation of Dihydroartemisinin Piperaquine in the Treatment of Uncomplicated falciparum Malaria
Am J Trop Med Hyg, September 1, 2007; 77(3): 447 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. J. Milan, I. L. Jones, P. T. Ellinor, and C. A. MacRae
In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H269 - H273.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. Darpo, M. Agin, D. J. Kazierad, G. Layton, G. Muirhead, P. Gray, and D. K. Jorkasky
Man Versus Machine: Is There an Optimal Method for QT Measurements in Thorough QT Studies?
J. Clin. Pharmacol., June 1, 2006; 46(6): 598 - 612.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
L Eckardt, G Breithardt, and P Kirchhof
Approach to wide complex tachycardias in patients without structural heart disease.
Heart, May 1, 2006; 92(5): 704 - 711.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Wu, J. C. Shryock, Y. Song, and L. Belardinelli
An Increase in Late Sodium Current Potentiates the Proarrhythmic Activities of Low-Risk QT-Prolonging Drugs in Female Rabbit Hearts
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 718 - 726.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
O. Casis, S.-P. Olesen, and M. C. Sanguinetti
Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator
Mol. Pharmacol., February 1, 2006; 69(2): 658 - 665.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. M.J.M. Straus, M. C.J.M. Sturkenboom, G. S. Bleumink, J. P. Dieleman, J. v. d. Lei, P. A. d. Graeff, J. H. Kingma, and B. H.Ch. Stricker
Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death
Eur. Heart J., October 1, 2005; 26(19): 2007 - 2012.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. M. Roden and R. Temple
The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process
Circulation, April 5, 2005; 111(13): 1697 - 1702.
[Full Text] [PDF]

Home page
 RadiologyHome page
G. Pirovano, D. B. Goodman, U. Halemane, C. Venetianer, M. A. Kirchin, and A. Spinazzi
Cardiac Electrophysiologic Monitoring after Injection of Gadobenate Dimeglumine versus Placebo in Healthy Volunteers and Patients with Cardiovascular Disease
Radiology, November 1, 2004; 233(2): 555 - 565.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. Llerena, R. Berecz, P. Dorado, and A. de la Rubia
QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations
J Psychopharmacol, June 1, 2004; 18(2): 189 - 193.
[Abstract] [PDF]

Home page
 NEJMHome page
D. M. Roden
Drug-Induced Prolongation of the QT Interval
N. Engl. J. Med., March 4, 2004; 350(10): 1013 - 1022.
[Full Text] [PDF]

Home page
 StrokeHome page
W. M. van den Bergh, A. Algra, and G. J.E. Rinkel
Electrocardiographic Abnormalities and Serum Magnesium in Patients With Subarachnoid Hemorrhage
Stroke, March 1, 2004; 35(3): 644 - 648.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. M. Torres, P. S. Bansal, M. Sunde, C. E. Clarke, J. A. Bursill, D. J. Smith, A. Bauskin, S. N. Breit, T. J. Campbell, P. F. Alewood, et al.
Structure of the HERG K+ Channel S5P Extracellular Linker: ROLE OF AN AMPHIPATHIC {alpha}-HELIX IN C-TYPE INACTIVATION
J. Biol. Chem., October 24, 2003; 278(43): 42136 - 42148.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Kirchhof, H. Degen, M. R. Franz, L. Eckardt, L. Fabritz, P. Milberg, S. Laer, J. Neumann, G. Breithardt, and W. Haverkamp
Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 257 - 263.
[Abstract] [Full Text]

Home page
 BloodHome page
C.-E. Chiang, H.-N. Luk, T.-M. Wang, and P. Y.-A. Ding
Prolongation of cardiac repolarization by arsenic trioxide
Blood, August 28, 2002; 100(6): 2249 - 2252.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. LLerena, R. Berecz, A. de la Rubia, and P. Dorado
QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients
J Psychopharmacol, July 1, 2002; 16(4): 361 - 364.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
D. M. TAYLOR
Prolongation of QTc Interval and Antipsychotics
Am J Psychiatry, June 1, 2002; 159(6): 1062 - 1062.
[Full Text]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
V. N. Batchvarov, A. Ghuran, P. Smetana, K. Hnatkova, M. Harries, P. Dilaveris, A. J. Camm, and M. Malik
QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2356 - H2363.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. Rubinstein and J. Camm
Cardiotoxicity of fluoroquinolones
J. Antimicrob. Chemother., April 1, 2002; 49(4): 593 - 596.
[Full Text] [PDF]

Home page
 HeartHome page
L Toivonen
More light on QT interval measurement
Heart, March 1, 2002; 87(3): 193 - 194.
[Full Text] [PDF]

Home page
 EuropaceHome page
S. G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, J. A. Camm, R. Cappato, S. M. Cobbe, C. Di Mario, et al.
TASK FORCE ON SUDDEN CARDIAC DEATH, EUROPEAN SOCIETY OF CARDIOLOGY: Summary of Recommendations
Europace, January 1, 2002; 4(1): 3 - 18.
[Abstract] [PDF]

Home page
 CirculationHome page
Members of the Sicilian Gambit
New Approaches to Antiarrhythmic Therapy, Part II: Emerging Therapeutic Applications of the Cell Biology of Cardiac Arrhythmias
Circulation, December 11, 2001; 104(24): 2990 - 2994.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Members of the Sicilian Gambit
New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias
Eur. Heart J., December 1, 2001; 22(23): 2148 - 2163.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
Members of the Sicilian Gambit
New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias
Cardiovasc Res, December 1, 2001; 52(3): 345 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. Glaser, M. Steinbach, C. Opitz, U. Wruck, and F. X. Kleber
Torsades de pointes caused by Mibefradil
Eur J Heart Fail, October 1, 2001; 3(5): 627 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
I. Cavero and W. Crumb
Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K53 - K63.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
G. Sponer
Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done?
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K101 - K104.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al.
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450.
[PDF]

Home page
 Eur Heart JHome page
Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al.
Guidelines on management (diagnosis and treatment) of syncope
Eur. Heart J., August 1, 2001; 22(15): 1256 - 1306.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
D. M. Roden
Pharmacogenetics and drug-induced arrhythmias
Cardiovasc Res, May 1, 2001; 50(2): 224 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. Lande, S. Demolombe, A. Bammert, A. Moorman, F. Charpentier, and D. Escande
Transgenic mice overexpressing human KvLQT1 dominant-negative isoform Part II: Pharmacological profile
Cardiovasc Res, May 1, 2001; 50(2): 328 - 334.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
V. N. Batchvarov, A. Ghuran, P. Smetana, K. Hnatkova, M. Harries, P. Dilaveris, A. J. Camm, and M. Malik
QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2356 - H2363.
[Abstract] [Full Text] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (160)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haverkamp, W
Right arrow Articles by Shah, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haverkamp, W
Right arrow Articles by Shah, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?